Bedaquiline-d6 (Mixture of Diastereomers)

Bedaquiline-d6 is a deuterated form of Bedaquiline, which is an FDA-approved drug used in the treatment of multi-drug-resistant tuberculosis (MDR-TB). Bedaquiline-d6 is a mixture of diastereomers that have been labeled with deuterium atoms, which are heavy isotopes of hydrogen. The deuterium atoms provide a unique molecular fingerprint that allows for the study of the drug's metabolism and pharmacokinetics. Bedaquiline-d6 is a type of antibiotic that works by inhibiting the ATP synthase enzyme in the bacteria that cause tuberculosis. This enzyme is responsible for producing the energy that the bacteria need to survive, and by blocking it, bedaquiline-d6 can effectively kill the bacteria. The use of bedaquiline-d6 is a promising new approach to the treatment of MDR-TB, which is a growing problem worldwide. Chemically, bedaquiline-d6 has a molecular formula of C32H31D6N3O2 and a molar mass of 517.70 g/mol. It is a white to off-white powder that is soluble in dimethyl sulfoxide, ethanol, and methanol. Bedaquiline-d6 is stable under normal storage conditions and has a shelf life of up to two years. In conclusion, bedaquiline-d6 is a deuterated form of bedaquiline that is used in the treatment of MDR-TB. It works by inhibiting the ATP synthase enzyme in the bacteria that cause tuberculosis, and is a promising new approach to addressing this growing problem. Its chemical properties make it useful for studying the drug's metabolism and pharmacokinetics, which could lead to further improvements in the treatment of tuberculosis.